| (210) | Number of the EPO application | 17733222 |
| (220) | Filing date of the EPO application | 2017.06.01 |
| (80) | EPO patent specification publication (B) | EPB nr. 16/2021, 2021.04.21 |
| (110) | EPO patent number | 3464318 |
| (21) | Number of the application | e 2019 0428 |
| (71) | Name(s) of applicant(s), code of the country | ABBVIE Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | MCPHERSON Michael J., US;
HOBSON Adrian D., US;
HAYES Martin E., US;
MARVIN Christopher C., US;
SCHMIDT Diana, US;
WAEGELL Wendy, US;
GOESS Christian, US;
OH Jason Z., US;
HERNANDEZ JR. Axel, US;
RANDOLPH John T., US; |
| (73) | Name(s) of owner(s), code of the country | ABBVIE Inc., US; |
| (54) | Title of the invention | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 39/00 (2006.01.01); A61K 47/68 (2017.01.01); A61P 37/06 (2006.01.01); C07K 16/24 (2006.01.01); C07J 71/00 (2006.01.01); C07K 16/18 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2019.05.31 |
| (30) | Priority | 201662344948 P, 2016.06.02, US; 201662371134 P, 2016.08.04, US |
| (86) | International application | PCT/US2017/035518, 2017.06.01 |
| (87) | International publication | WO 2017/210471, 2017.12.07 |